Timothy Landry

Mr. Timothy Landry

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in NAM Journal
Verified
Journal Article
Open access
HLHui Kheng Lim
Hui Kheng Lim
CHChristopher Owen Hughes
Christopher Owen Hughes
TLTimothy Landry
Timothy Landry
CTChoon Wee Joseph Tan
Choon Wee Joseph Tan
SASeyoum Ayehunie
Seyoum Ayehunie
BSBenjamin Smith
Benjamin Smith
• First in vitro assay to address site-of-contact genotoxic hazard identification for oral or GI route of exposure. • Assay acceptance criteria have been established to determine/ classify genotoxic status of test articles. • Assay accuracy established for genotoxic risk identification. • Can potentially reduce the unnecessary usage of animal experimentation once sufficiently validated.

16 January 2026 in Toxicology in Vitro
Verified
Journal Article
Open access
JPJessica Perrin
Jessica Perrin
GCGertrude-Emilia Costin
Gertrude-Emilia Costin
SASeyoum Ayehunie
Seyoum Ayehunie
HKHelena Kandarova
Helena Kandarova
TLTimothy Landry
Timothy Landry
ACAmy J. Clippinger
Amy J. Clippinger
Consumers tend to think of personal lubricants as personal care products or cosmetics that are not tested using animals, but the regulatory classification and hence the testing requirements for these products vary by country. For example, in the United States, regulations and guidance classify personal lubricants as medical devices, for which manufacturers must perform a rabbit vaginal irritation (RVI) test as part of a typical safety assessment submitted to the Food and Drug Administration (FDA). This publication discusses replacing the RVI with an in vitro reconstructed human vaginal epithelium (RHVE) test method, which uses the EpiVaginal model to assess the irritation potential of personal lubricants. The proof-of-concept studies presented here indicate that this in vitro test method can rank water-based personal lubricants by vaginal irritation potential. Scientific confidence in this test method is evaluated based on an established framework that considers the method's context of use, human biological relevance, technical characterization, data integrity and transparency, and independent review. A proposed workplan aims to further develop and qualify the in vitro test method for regulatory acceptance in assessing vaginal irritation of personal lubricants, and expanding its use to other products.

28 March 2026 in Toxics
Verified
Journal Article
Open access
PDF file
CPChristian Pellevoisin
Christian Pellevoisin
Hajime KojimaHajime Kojima
Hajime Kojima
SHSebastian Hoffmann
Sebastian Hoffmann
TATakao Ashikaga
Takao Ashikaga
TLTimothy Landry
Timothy Landry
AAAlexander Armento
Alexander Armento
The Epi2SensA method is a method similar to the validated EpiSensA assay for assessing the skin sensitization potential of chemicals. The Epi2SensA protocol includes adaptation (changes to exposure conditions and the controls) for using an alternative reconstructed human epidermis (RhE) model, the EpiDerm™ model. The interlaboratory validation study evaluated the reliability and predictive capacity of Epi2SensA according to OECD Performance Standards. Four laboratories (Mattek, Now Part of Sartorius, Eurofins Munich, Burleson Research Technologies, Inc., and Food and Drug Safety Center) conducted blinded testing of 20 coded reference substances representing various chemical categories and sensitization potencies. Statistical analysis using modified acceptance criteria (a 60% cell viability threshold) and a modified prediction model (requiring at least two positive gene markers) demonstrated substantially improved performance compared to the original EpiSensA criteria. The between-laboratory reproducibility (BLR) was 85%, the average within-laboratory reproducibility (WLR) was 83.3%, and the average predictivity parameters were 88.1% for sensitivity, 88.9% for specificity, and 88.3% for accuracy. Epi2SensA achieved performance metrics comparable to the validated reference method (EpiSensA), supporting regulatory acceptance of the Epi2SensA assay using the EpiDerm™ model (Mattek Corporation, Now Part of Sartorius, Ashland, MA, USA) as an alternative RhE source for OECD TG 442D skin sensitization testing.